• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于轨道阱质谱法的糖肽类药物中N-亚硝胺类原料药相关杂质的原位生成与评估

In-situ formation and evaluation of N-nitrosamine drug substance related impurities in glycopeptides implying orbitrap mass spectrometry.

作者信息

Paritala Sree Teja, Sharma Nitish, Shah Ravi P

机构信息

Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research (NIPER), Ahmedabad, India.

Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research (NIPER), Ahmedabad, India.

出版信息

J Pharm Sci. 2025 Feb;114(2):934-948. doi: 10.1016/j.xphs.2024.10.056. Epub 2024 Nov 28.

DOI:10.1016/j.xphs.2024.10.056
PMID:39612987
Abstract

Nitrosamines, a class of N-nitroso compounds, have raised significant health concerns due to their established carcinogenicity. ICH M7 enlisted N-nitroso compounds in the so called cohorts of concern due to their carcinogenic effects. Glycopeptides (GPs) are complex molecules composed of peptide and glycan moieties. GPs serve as the last resort for the mitigation of bacterial infections, particularly against gram-positive bacteria. GPs are susceptible to nitrosamine drug substance related impurities (NDSRIs) contamination due to the presence of secondary amine in their core structure. The incidence of formation of NDSRI impurities in GPs could be either during their semi-synthetic route or storage. However, till date, no studies have been reported on the occurrence of NDSRI in GPs which is a pre-requisite. Hence, the current study investigates the plausible mechanisms and detection methods for the NDSRI in GPs. In-situ studies were performed to evaluate the possible formation of NDSRI in GPs. In the current study, GPs of different generations were screened for their potential of forming NDSRI impurities implying nitrosating agent. LC and LCHRMS/MS studies were performed to identify the in-situ generated impurities. Interestingly, the formation of NDSRIs is evident in all the selected GPs. The molecular mechanisms and pathways for individual GPs and respective NDSRIs were elucidated. Interestingly, isomeric NDSRIs were also identified during in-situ generated samples. Using CPCA the potency scores and acceptable intakes for the NDSRIs were evaluated. Thus, this work aims to enhance the safety and efficacy of GPs ensuring compliance with the regulatory standards by advancing the understanding of NDSRIs in GPs.

摘要

亚硝胺是一类N-亚硝基化合物,因其已确定的致癌性而引发了重大的健康担忧。国际人用药品注册技术协调会(ICH)的M7指南将N-亚硝基化合物列入所谓的关注队列,因其具有致癌作用。糖肽(GPs)是由肽和聚糖部分组成的复杂分子。糖肽是缓解细菌感染的最后手段,特别是针对革兰氏阳性菌。由于其核心结构中存在仲胺,糖肽易受亚硝胺原料药相关杂质(NDSRIs)污染。糖肽中NDSRI杂质的形成可能发生在其半合成路线或储存过程中。然而,迄今为止,尚未有关于糖肽中NDSRI出现情况的研究报道,而这是一个先决条件。因此,本研究调查了糖肽中NDSRI的可能形成机制和检测方法。进行了原位研究以评估糖肽中NDSRI的可能形成。在本研究中,筛选了不同代的糖肽形成NDSRI杂质(意味着亚硝化剂)的潜力。进行了液相色谱(LC)和液相色谱高分辨质谱/质谱(LCHRMS/MS)研究以鉴定原位生成的杂质。有趣的是,在所有选定的糖肽中都明显形成了NDSRIs。阐明了各个糖肽和相应NDSRIs的分子机制和途径。有趣的是,在原位生成的样品中还鉴定出了异构NDSRIs。使用临界不良作用浓度(CPCA)评估了NDSRIs的效力得分和可接受摄入量。因此,这项工作旨在通过加深对糖肽中NDSRIs的理解来提高糖肽的安全性和有效性,确保符合监管标准。

相似文献

1
In-situ formation and evaluation of N-nitrosamine drug substance related impurities in glycopeptides implying orbitrap mass spectrometry.基于轨道阱质谱法的糖肽类药物中N-亚硝胺类原料药相关杂质的原位生成与评估
J Pharm Sci. 2025 Feb;114(2):934-948. doi: 10.1016/j.xphs.2024.10.056. Epub 2024 Nov 28.
2
NDSRIs Crisis in Pharmaceuticals; Insights on Formation Pathways, Root Causes, Risk Management, and Novel Analytical Techniques.药品中的去甲肾上腺素和特异性5-羟色胺再摄取抑制剂危机;关于形成途径、根本原因、风险管理和新型分析技术的见解
Curr Med Chem. 2025;32(6):1065-1081. doi: 10.2174/0109298673322023240829081220.
3
N-Nitrosamine drug substance related impurities (NDSRIs) - A proposal for the addition of subcategories to carcinogenic potency categorization approach categories 1 and 2 for NDSRIs with a molecular weight > 200 Da.N-亚硝胺类药物杂质(NDSRIs)- 建议为分子量> 200 Da 的 NDSRIs 致癌效力分类类别 1 和 2 添加子类别。
Regul Toxicol Pharmacol. 2024 Dec;154:105704. doi: 10.1016/j.yrtph.2024.105704. Epub 2024 Sep 24.
4
Nitrosamine Drug Substance-Related Impurities (NDSRIs) in Pharmaceuticals: Formation, Mitigation Strategies, and Emphasis on Mutagenicity Risks.药品中的亚硝胺类原料药相关杂质(NDSRIs):形成、缓解策略及对致突变性风险的关注
Pharm Res. 2025 Apr;42(4):547-578. doi: 10.1007/s11095-025-03857-9. Epub 2025 Apr 23.
5
Determining recommended acceptable intake limits for N-nitrosamine impurities in pharmaceuticals: Development and application of the Carcinogenic Potency Categorization Approach (CPCA).确定药品中 N-亚硝胺杂质的推荐可接受摄入量限值:致癌潜能分类法(CPCA)的制定和应用。
Regul Toxicol Pharmacol. 2024 Jun;150:105640. doi: 10.1016/j.yrtph.2024.105640. Epub 2024 May 14.
6
Quantum Mechanical Assessment of Nitrosamine Potency.量子力学评估亚硝胺类化合物的效力。
Chem Res Toxicol. 2024 Jun 17;37(6):1011-1022. doi: 10.1021/acs.chemrestox.4c00087. Epub 2024 May 28.
7
Quantitative Investigation of Nitrosamine Drug Substance-Related Impurities (NDSRIs) Under Artificial Gastric Conditions by Liquid Chromatography-Tandem Mass Spectrometry and Structure-Activity Relationship Analysis.液相色谱-串联质谱法结合构效关系分析对人工胃液条件下亚硝胺类药物相关杂质的定量研究
Drug Test Anal. 2025 Sep;17(9):1772-1784. doi: 10.1002/dta.3874. Epub 2025 Mar 12.
8
Risk assessment and management strategy of two new NDSRIs in a pharmaceutical drug product for the treatment of a rare disease: From prediction to control.一种用于治疗罕见疾病的药品中两种新型去甲肾上腺素和多巴胺再摄取抑制剂的风险评估与管理策略:从预测到控制
J Pharm Sci. 2025 Mar;114(3):1572-1582. doi: 10.1016/j.xphs.2025.01.016. Epub 2025 Jan 28.
9
Modified NAP test: A simple and Responsive Nitrosating Methodology for Risk Evaluation of NDSRIs.改良 NAP 试验:一种用于 NDSRIs 风险评估的简单且灵敏的亚硝化方法。
J Pharm Sci. 2023 May;112(5):1333-1340. doi: 10.1016/j.xphs.2023.02.024. Epub 2023 Mar 4.
10
A practical HPLC-MS method for the analysis of nitrosamine drug substance related impurities using an inexpensive single quadrupole mass spectrometer.一种使用廉价单四极杆质谱仪分析亚硝胺药物杂质的实用 HPLC-MS 方法。
J Chromatogr A. 2024 Nov 8;1736:465399. doi: 10.1016/j.chroma.2024.465399. Epub 2024 Sep 25.